Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
22.32 CNY +2.81% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +0.81% -10.83%
Jul. 01 Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board and Board Committee Changes CI
Jun. 28 Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board and Board Committee Changes
Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug
Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024
Fosun Pharma Signs HK$13.4 Billion Merger Offer for Henlius Biotech; Henlius Shares Soar 19%
Fosun Pharma Trims Stake in Gland Pharma to 51.83%
Shanghai Fosun Pharmaceutical Co., Ltd. Announces Executive and Committee Changes
Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3%
Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7%
Shanghai Fosun Pharmaceutical (Group)'s Investigational New Drug Application Accepted by NMPA
Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment
China Approves Clinical Trials For Breast Cancer Drugs
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  5. Other languages